A Randomized Double-Masked Study of 0.05% Cyclosporine Ophthalmic Emulsion in the Treatment of Meibomian Gland Dysfunction

Prabhasawat, Pinnita; Tesavibul, Nattaporn; Mahawong, Wannaree

doi:10.1097/ico.0b013e31823cc098

Cited by 80 publications

(53 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CsA 0.05 % has dual action in the treatment of dry eye also by decreasing the inflammation in meibomitis that results in an increase in gland secretion [77,78].…”

Section: Cyclosporinementioning

confidence: 99%

The role and treatment of inflammation in dry eye disease

Yağcı

Gürdal

2014

Int Ophthalmol

View full text Add to dashboard Cite

Dry eye syndrome is a common ocular surface problem, affects 10-30 % of the population, especially in those who are older than 40 years. As a consequence of the demographic pressure created by the aging population, its prevalence is expected to increase as well as its burden on ophthalmologic practices. Thus, understanding the complex underlying mechanisms and development of thoughtful, effective strategies that involve these mechanisms are critical. Many factors causing ocular surface damage and inflammation have been shown to contribute to the etiopathogenesis. Increased osmolarity induces ocular surface inflammation leading to disruption of both the quality and quantity of tears. Pathologic tear function and the ocular surface inflammation affects the neural arcade and increases apoptosis in the ocular surface cells thus creating a viscous cycle for dry eye by causing unstable and hyperosmolar tears. Thus, the treatment objective is to prevent severe dry eye complications via preventing inflammation and apoptosis of the ocular surface cells. The ultimate target is a normalized ocular surface, increased tear stability, and decreased osmolarity of the tear film. In the light of current literature, this review aims to elucidate the role of inflammation as the main etiological factor in dry eye disease and discuss current therapeutic approaches to overcome it.

show abstract

“…CsA 0.05 % has dual action in the treatment of dry eye also by decreasing the inflammation in meibomitis that results in an increase in gland secretion [77,78].…”

Section: Cyclosporinementioning

confidence: 99%

The role and treatment of inflammation in dry eye disease

Yağcı

Gürdal

2014

Int Ophthalmol

View full text Add to dashboard Cite

show abstract

“…It is difficult to directly compare these studies as many used different inclusion criteria in their definition of dry eye and different primary outcome measures. In addition, some studies included a control group [25,30,34–36], while others did not [31,39–42]. In general, however, symptom scores improved, ocular staining decreased and Schirmer scores increased in most studies after treatment with CsA [25,30–34,40,43–45].…”

Section: Human Studies Of Csa For Dry Eyementioning

confidence: 99%

“…Regarding ADDE versus EDE, two Level 1 studies primarily treated ADDE [25,35] and one primarily treated EDE [36] with CsA. In the two ADDE studies, Schirmer scores and staining (corneal [25] and conjunctival [35]) significantly improved over control, but no difference was seen with regards to TBUT [25,35].…”

Section: Human Studies Of Csa For Dry Eyementioning

confidence: 99%

Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence

Ames

2015

Clinical Investigation

View full text Add to dashboard Cite

Dry eye has gained recognition as a public health problem given its high prevalence, morbidity and cost implications. Although dry eye is common and affects patients’ quality of life, only one medication, cyclosporine 0.05% emulsion, has been approved by the US FDA for its treatment. In this review, we summarize the basic science and clinical data regarding the use of cyclosporine in the treatment of dry eye. Randomized controlled trials showed that cyclosporine emulsion outperformed vehicles in the majority of trials, consistently decreasing corneal staining and increasing Schirmer scores. Symptom improvement was more variable, however, with ocular dryness shown to be the most consistently improved symptom over vehicle.

show abstract

“…Meibomian gland dysfunction (MGD) compromises the tear film and meibum lipids which results in evaporative dry eye 3 4. MGD is an extremely common and important cause of posterior blepharitis, the incidence of which is probably underestimated 5 6…”

Section: Introductionmentioning

confidence: 99%

Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial

et al. 2014

View full text Add to dashboard Cite

show abstract

A Randomized Double-Masked Study of 0.05% Cyclosporine Ophthalmic Emulsion in the Treatment of Meibomian Gland Dysfunction

Abstract: Topical CsA 0.05% twice daily may be helpful in the treatment of MGD mainly by improving tear film stability.

Cited by 80 publications

References 20 publications

The role and treatment of inflammation in dry eye disease

The role and treatment of inflammation in dry eye disease

Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence

Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial

Contact Info

Product

Resources

About